Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE trial of suprachoroidal CLS-TA plus intravitreal aflibercept in retinal vein occlusion
MOH_2017-11-05_000788Phase 3Completed
- Sponsor
- Clearside Biomedical
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone and aflibercept in Vein occlusion (RVO) (2 arms), sponsored by Clearside Biomedical. Started Jul 2017; status: completed.
02
Drugs
triamcinoloneaflibercept
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on MOH_2017-11-05_000788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-05_000788.